TWiV 1162: Clinical Update with Dr. Daniel Griffin - Key Takeaways
0:53 Mycoplasma Pneumonia Increase: CDC reports an increase in Mycoplasma pneumoniae infections, also known as "walking pneumonia."
1:48 Polio Campaign Postponed: The polio vaccination campaign in North Gaza has been postponed due to the ongoing conflict.
2:42 Mpox Clade 1B in the UK: The first imported case of Mpox Clade 1B has been detected in the UK, highlighting the global interconnectedness of infectious diseases.
3:04 Mpox Vaccine Trial for Children: Bavarian Nordic has started a clinical trial to assess the safety and efficacy of the JYNNEOS vaccine in children aged 2 to 11 years, primarily in the DRC and Uganda.
4:48 Marburg Virus Outbreak Update: The Marburg virus outbreak in Rwanda has seen a slight increase in cases, with a total of 66 confirmed cases and 15 deaths.
5:45 Influenza Activity Remains Low: Current influenza activity in the US is still low, but historically, an uptick is expected around November and December.
9:26 RSV and Mucosal Antibodies: A study published in The Lancet Infectious Diseases found that children with lower levels of mucosal antibodies against RSV after receiving the nirsevimab monoclonal antibody were more likely to develop symptomatic RSV infection.
12:31 COVID-19 Deaths Continue to Decline: Provisional deaths due to COVID-19 in the US continue to decline, with most states reporting less than 2%. Wastewater surveillance also shows a downward trend.
14:29 COVID-19 mRNA Boosters and Mucosal Immunity: Conflicting studies in Science Translational Medicine present contrasting findings on whether repeated mRNA COVID-19 boosters effectively enhance mucosal immunity. One study suggests they do, while another indicates limited impact.
21:45 Facial Palsy After COVID-19 Vaccination: A study in Emerging Infectious Diseases found a slight increase in facial palsy (Bell's palsy) within 28 days of COVID-19 vaccination, primarily after the first and second doses. However, the risk of facial palsy from COVID-19 infection itself is higher than the risk associated with vaccination.
28:41 Paxlovid and Long COVID: A retrospective cohort study published in Scientific Reports suggests that Paxlovid treatment may be associated with a reduction in long COVID symptoms.
30:50 Montelukast (Singulair) for COVID-19: A randomized clinical trial published in JAMA Network Open found that montelukast did not significantly improve time to sustained recovery in COVID-19 outpatients.
32:31 Long COVID in Young Marines: A study in The Lancet Regional Health β Americas found that a quarter of young, healthy US Marines developed post-acute sequelae of COVID-19 (PASC), experiencing symptoms like loss of taste and smell, shortness of breath, cough, and decreased physical performance even one year after initial infection.
43:36 Pertussis Booster Timing: With a resurgence of pertussis cases, the current recommendation of Tdap boosters every 10 years may need to be reevaluated, as protection significantly wanes over time.
45:04 Eye Protection and COVID-19: While the primary mode of COVID-19 transmission is through inhalation, wearing larger glasses may offer some additional protection against droplets, especially in the early stages of the pandemic when face shields were commonly used by medical personnel.
Note: Timestamps are approximate and correspond to the start of the discussion about each topic.